

ENANTA Pharmaceuticals, Inc.

500 Arsenal Street
Watertown, Massachusetts
02472

Tel: 617.607.0800
Fax: 617.607.0530
www.enanta.com

CONTACT:**Release**

Paul Kidwell

617-296-3854

paul_kidwell@hotmail.com

News

Enanta Pharmaceuticals raises \$18 million in latest round of private equity financing



WATERTOWN, Mass., June 12, 2002 - Enanta Pharmaceuticals Inc. (www.enanta.com), a chemistry-driven biopharmaceutical company developing macrolide antibiotics and immunosuppressants, announced that it has completed a first closing on \$18 million in private financing from new and existing investors. The financing was co-led by BioVentures Investors and Biomedicine L.P., an affiliate of International BM Biomedicine Holdings (IBMH). Global Biomedical Partners, Ltd., as the exclusive investment advisor to IBMH, represented Biomedicine L.P. in this transaction. Pacific Growth Equities, Inc. served as placement agent for the offering.

Enanta Pharmaceuticals has raised an aggregate of \$43 million to date. Investors in this latest round also included TVM Techno Venture Management, Oxford Bioscience Partners, Advent International, Lancet Capital, Swisslife Private Equity Partners, MC Financial Services and Wheatley Medtech Partners, LP. The Company plans to complete additional closings in the coming months.

"We are extremely pleased to have attracted a strong group of new investors to Enanta," said Dr. Spiros Jamas, President and CEO. "Enanta is building an impressive product pipeline and looks forward to initiation of clinical studies with our new-generation macrolide antibiotic. Our goals for the next two years are very clear: to maintain focus, and continue to leverage our core chemistry expertise for additional products."

BioVentures Investors, headquartered in Cambridge, Mass., identifies, selects and makes investments in, and assists the development of, companies focused on the commercial development of advanced technologies in the life sciences and healthcare. The firm's investments are concentrated in four areas: drug development, genomics, medical devices and medical software.

Global Biomedical Partners, Ltd. ("GBP") is a management company exclusively advising International BM Biomedicine Holdings ("IBMH") and its affiliates on its direct investments in life sciences companies. GBP maintains its principal offices in New York City and Zurich. IBMH has invested in 23 life sciences companies.

Headquartered in Watertown, Mass., Enanta Pharmaceuticals is using its breakthrough chemistry technology - *Drug Morphing*[™] and *Peptide Morphing*[®] -- to create new intellectual properties by 'morphing' existing drugs, natural products and biologically active peptides into novel small-molecule drugs. The Company is initially focusing on new chemical entities derived from existing drugs that address significant unmet medical needs: (a) new-generation macrolide antibiotics to overcome bacterial resistance; and (b) anti-inflammatory

drugs for a variety of indications, including asthma, psoriasis and inflammatory bowel diseases.